A phase 2a trial of brepocitinib for cicatricial alopecia

• DOI: 10.1016/j.jaad.2024.09.073
• Publication Date: 2024-10-25T00:29:38Z
• Authors: Eden David; Neda Shokrian; Ester Del Duca; Marguerite Meariman; Celina Dubin; Kelly Hawkins; Elizabeth Andrews; Savina Sikand; Giselle Singer; Barry Oemar; Yeriel Estrada; Swaroop Bose; Juliana Pulsinelli; Ping Mahling; Joel Correa Da Rosa; Benjamin Ungar; Elena Peeva; Emma Guttman-Yassky

Cicatricial alopecias (CA) are chronic, progressive scarring hair-loss conditions. Molecular dysregulation is not fully understood, hindering treatment development. Th1/IFNγ signaling and JAK dysregulation has shown involvement, providing rationale for this phase 2a trial with TYK2/JAK1 inhibitor brepocitinib.Randomized, placebo-controlled phase 2a trial spanning 52 weeks. Adults (18≥years of age) with lichen planopilaris, frontal fibrosing alopecia, or central centrifugal cicatricial alopecia diagnosis were randomized 3:1 to brepocitinib 45mg daily or placebo for 24 weeks, after which all patients received brepocitinib for another 24 weeks, with a safety follow up 4 weeks later. Lesional scalp biopsies were collected at baseline, week 24, and week 48. Co-primary endpoints were changes in lesional expression of CCL5, changes in lesional expression of fibrosis-related markers, and safety at week 24.Patients receiving brepocitinib showed significant downregulation in CCL5 expression at week 24 (p=0.004). Enrichment analysis of a subset of fibrosis markers showed trending upregulation in placebo patients (p<0.1). Brepocitinib was well tolerated and improved clinical severity scores.Single-dose regimen, small placebo group.Brepocitinib significantly reduces CCL5 expression and was well tolerated at week 24, meeting co-primary endpoints. Brepocitinib reduces inflammatory biomarker expression and improves clinical severity, while maintaining favorable safety profile.